v3.26.1
Condensed Consolidated Balance Sheets (Unaudited) - USD ($)
Mar. 31, 2026
Dec. 31, 2025
Current Assets:    
Cash $ 223,883 $ 251,291
Prepaid expenses and other current assets 236,502 316,583
Total Current Assets 460,385 567,874
Equipment and furnishings, less accumulated depreciation of $120,479 and $120,013, respectively 2,534 3,000
Operating lease right-of-use asset 114,661 126,628
Total Assets 577,580 697,502
Current Liabilities:    
Accounts payable 815,315 716,220
Other accrued expenses 3,568,311 3,161,379
Notes payable 161,265 217,772
Operating lease liability, current portion 49,025 48,083
Total Current Liabilities 7,241,761 6,897,378
Notes payable, non-current portion 23,621
Operating lease liability, non-current portion 66,649 79,221
Total Liabilities 7,308,410 7,000,220
Commitments, contingencies, and litigations (Note 13)
Stockholders’ Deficit:    
Common stock; par value $0.001 per share; 1,000,000,000 shares authorized; 420,279,879 shares issued and outstanding at March 31, 2026 and December 31, 2025 420,280 420,280
Additional paid-in capital 257,043,993 256,179,846
Accumulated other comprehensive loss (59,906) (60,191)
Accumulated deficit (264,144,266) (262,853,812)
Total Provectus Biopharmaceuticals, Inc., Stockholders’ Deficit (6,724,587) (6,298,737)
Non-controlling interest in subsidiary (6,243) (3,981)
Total Stockholders’ Deficit (6,730,830) (6,302,718)
Total Liabilities and Stockholders’ Deficit 577,580 697,502
Series D Convertible Preferred Stock [Member]    
Stockholders’ Deficit:    
Preferred Stock value 957 957
Series D-1 Convertible Preferred Stock [Member]    
Stockholders’ Deficit:    
Preferred Stock value 14,355 14,183
Nonrelated Party [Member]    
Current Liabilities:    
Accrued interest 38,300 23,540
Convertible notes payable 980,000 870,000
Related Party [Member]    
Current Liabilities:    
Accrued interest 119,545 120,384
Convertible notes payable $ 1,510,000 $ 1,740,000